The Emerging Role of the use of Real-Time Continuous Glucose Monitoring in Type 2 Diabetes

Details
Resources

The Emerging Role of the use of Real-Time Continuous Glucose Monitoring in Type 2 Diabetes

11:00 – 12:00 PM PT / 2:00 – 3:00 PM ET

A Dexcom presentation theater held in conjunction with AACE Annual Meeting June 9, 2021.

This presentation will be available for viewing post livestream to SIGMA members on the SIGMA platform. If you are not already a member, we invite you to learn more about SIGMA or request membership to watch more educational webinars.

SIGMA Platform

BRIEF SAFETY STATEMENT

Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you’re taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.